Skip to main content

Peptide Profile

TB-500

TB-500 (TB4) · Tb4 · TB4 · TB500

TB-500 is a synthetic peptide corresponding to residues 17–23 of thymosin beta-4 (Tb4), a 43-amino-acid protein with established roles in actin cytoskeleton regulation, wound healing, and tissue repair; no published studies have…

Tissue RepairAdvisory Vote: FavorableResearch Only
Used forrecovery
Half-life
5–7 days
Routes
subcutaneous
Find providers View evidence

Educational research information — not medical advice. Review primary sources and consult a qualified professional before any decision.

Educational research tools — not medical advice.

Overview

What TB-500 is

About TB-500

TB-500 exerts its effects primarily through promotion of actin polymerisation and cell migration. It upregulates the expression of beta-4 thymosin, which facilitates endothelial and muscle satellite cell movement to injury sites. Unlike BPC-157, TB-500 appears to act via a more systemic mechanism rather than locally at the administration site.

TB-500 is a synthetic peptide corresponding to residues 17–23 of thymosin beta-4 (Tb4), a 43-amino-acid protein with established roles in actin cytoskeleton regulation, wound healing, and tissue repair; no published studies have directly examined TB-500 as a compound in its own right. The Tb4 parent protein promotes actin sequestration and cell migration through beta-thymosin repeat interactions, and generates the anti-fibrotic tetrapeptide Ac-SDKP via enzymatic cleavage; TB-500 is hypothesized to retain a subset of these activities in a shorter, potentially more bioavailable fragment form. All available evidence for TB-500 derives from thymosin beta-4 and Ac-SDKP preclinical research, where animal studies demonstrate tissue-reparative and anti-fibrotic effects in cardiovascular, renal, and musculoskeletal models; human clinical translation has not been established for either the parent compound or the fragment. TB-500 has no FDA approval or regulatory approval in any jurisdiction; its hypothesized activity has not been validated in any published study using the fragment specifically, and it is available only as a research compound with a citation base derived entirely from parent-compound literature. TB-500 is commonly studied in combination with BPC-157 and GHK-Cu in what is referred to as the GLOW research blend, with the rationale that thymosin beta-4 fragment activity — actin sequestration and cell migration support — complements BPC-157's angiogenic properties. The GLOW combination is investigated in research contexts for synergistic tissue repair across musculoskeletal, connective tissue, and wound healing applications. TB-500 is most commonly administered via subcutaneous injection in research contexts, consistent with the injectable format used in Tb4 preclinical studies. Nasal spray delivery of TB-500 — often in combination with BPC-157 — has emerged as an investigational format in research blend products, offering a needle-free alternative for combination protocols; systemic bioavailability data for nasal TB-500 in humans is not established. The BPC-157 and TB-500 combination is among the most widely researched peptide stack pairings for tissue repair, with research rationale based on complementary signaling — BPC-157's angiogenic and nitric oxide pathway effects pairing with TB-500's actin cytoskeleton modulation and cell migration promotion. Preclinical research on this combination suggests additive or synergistic tissue-reparative effects across tendon, muscle, and wound healing models, though no human clinical trials have examined the combination directly. The GLOW blend adds GHK-Cu to this pairing, a three-compound combination studied in research contexts for complementary effects on collagen synthesis and anti-inflammatory signaling.

Women's Health

No human trial data exist for injectable TB-500 in any women's-health indication. Human RCT data for thymosin β4 exist only for the distinct ophthalmic candidate RGN-259, which does not validate injectable TB-500's safety or efficacy for any use. TB-500 shares BPC-157's angiogenesis-mediated theoretical tumor-promotion concern from preclinical mechanistic data. TB-500/thymosin β4 is WADA-prohibited at all times (S2.3, Growth Factors, since 2018) and has no FDA approval.

TB-500 Benefits & Research Areas

actin binding and cellular migration facilitation — core mechanism driving tissue repairwound healing and anti-inflammatory effects across muscle, tendon, and cardiac tissuethymosin beta-4 C-terminal fragment — angiogenesis and systemic distributionsubcutaneous injection — frequently combined with BPC-157 in recovery research stacks

Research Signals

Commonly researched in the context of

Injury HistoryHigh Training LoadSedentary

Population research notes

30s40s50+

These signals reflect research interest areas, not treatment indications.

Pharmacokinetics

TB-500 half-life calculator

Compound & timing

Half-lifefrom PeptideBase data
Source: "5–7 days" · TB-500 (PeptideBase)
to show amount remaining
7 days
0%25%50%75%100%07.315222936time since dose (days)
Plasma decay curve for TB-500: 38% to 50% remaining at 7 days after the dose.
range (5–7 days)slower half-life
38%–50%remaining in plasmaat 7 days after the dose
Half-life
5 – 7 days
~97% cleared after
35 days

Model: single-dose, first-order (single-compartment) estimate. Real clearance is multi-compartment and varies by individual and route.

The Research

What the evidence says about TB-500

Research Evidence

based on 3 studies · most recent 2019

Regulatory Status

Availability Status
Research Only
FDA Status
Advisory Vote: Favorable
Effective Date
July 23, 2026
Source
View FDA source →

Not FDA-approved; WADA prohibited (S2). Placed on the interim FDA 503A "Category 2" list (significant safety risks) in September 2023, alongside BPC-157. The FDA did not reclassify it to "Category 1" in February 2026 (that was an HHS announcement of intent, not an FDA action). In April 2026 the FDA removed the thymosin β4 fragment (TB-500) from Category 2 because the nomination was withdrawn — this does not authorize compounding.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Research Sources

3 sources cited · 3 weak

1 Review · 2 Animals

  • Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis

    Kidney International · 2013

    Research in mouse models of renal fibrosis found that thymosin β4 (TB-500) reduced late-stage fibrosis through a PAI-1-dependent mechanism, while its metabolite Ac-SDKP exerted consistent antifibrotic effects at both early and late stages of kidney injury, demonstrating complementary tissue repair activities of the Tβ4-Ac-SDKP pathway.

    AnimalWeakPMID 23739235

  • Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice

    Wound Repair and Regeneration · 2003

    Thymosin beta-4 accelerated full-thickness dermal wound healing in both diabetic and aged mouse models, increasing wound contracture, collagen deposition, and keratinocyte migration; a seven-amino-acid synthetic fragment replicating its actin-binding domain (LKKTETQ) produced comparable repair activity in aged animals.

    AnimalWeakPMID 12581423

  • Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system?

    Canadian Journal of Physiology and Pharmacology · 2019

    This review summarizes experimental evidence that thymosin β4 (TB-500) and its metabolite Ac-SDKP promote cardiac repair after infarction by stimulating endothelial cell migration and cardiomyocyte survival, and exert antifibrotic and anti-inflammatory effects in heart, arteries, lungs, and kidneys, with both molecules showing angiogenic activity in vitro and in vivo.

    ReviewTheoreticalPMID 30854877

TB-500 Side Effects & Safety Considerations

Research-use compound with limited human data. Evidence strength varies — see the Evidence section.

Absolute contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.

Known Interactions

1 noted
Synergistic1
BPC-157
Documented

Research suggests BPC-157 and TB-500 may produce enhanced tissue repair effects when combined. BPC-157 is studied for angiogenesis and gut-protective properties, while TB-500 promotes actin assembly and cell migration — complementary mechanisms in healing models.

Sikiric P et al. (2018) Brain-gut Axis and Pentadecapeptide BPC 157. Curr Neuropharmacol; Chang SH et al. (2011) Thymosin beta-4 induces adult epicardial progenitor mobilization. Nature

These interactions reflect published research and are provided for educational purposes only. This is not medical advice. Consult a qualified healthcare professional before combining any compounds or medications.

Compare

VS

TB-500

Third-party testing data

13 verified COAs

Median tested purity

99.3%

Median tested purity of 99.3% across 13 verified third-party lab COAs (interquartile range 99.1%–99.5%), as reported by the independent testing labs below. PeptideBase reports these lab-published figures and does not itself test, endorse, or certify any product.

Independent labs
Freedom Diagnostics, Janoshik Analytical, TrustPointe Analytics LLC
Most recent test
July 2026

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Certificates of Analysis

Cross-vendor verified45 COAs on record for TB-500

PeptideBase reports these lab-published figures and does not itself test, endorse, or certify any product. Confirmed by lab results were matched against the issuing laboratory's own records — either the lab served the document, or its own hosted copy matches ours byte for byte. For every other result the badge states what is known about the lab: that it can be checked and no result is recorded yet, that it can't be checked, or that we have not reviewed it.

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Community Experience

What people report about TB-500

n=51high confidence

Self-reported, anecdotal experiences aggregated from public Reddit discussions — community sentiment, not clinical evidence or medical advice.

Attribution note: many of these reports describe stacking TB-500 with other compounds, so outcomes may not be attributable to it alone.

Outcome distribution

67%improved
Improved
34 · 67%
Mixed
5 · 10%
No clear effect
10 · 20%
Worse
2 · 4%

Outcomes by goal · improved % · reports

General recovery69% improved · 29 reports
Tendon & joint repair60% improved · 10 reports
Hair growth83% improved · 6 reports
Muscle & soft-tissue injury40% improved · 5 reports

Side effects people mention

Counts are mentions across reports, not incidence rates.

Injection site reaction4
Decreased appetite1
Diarrhea1
Dizziness1
Elevated heart rate1
Fatigue1
Nausea1
Vomiting1

Most reported

What they wish they'd known

  • Gastrointestinal distress can onset rapidly and severely under certain administration conditions2×thread 1thread 2
  • Results vary widely between individuals and injuries, with some seeing no response at all7×thread 1thread 2thread 3
  • Attributing outcomes to TB-500 specifically is difficult when multiple compounds are used simultaneously5×thread 1thread 2thread 3
  • Improvement timelines differ greatly; some saw early changes while others needed many weeks6×thread 1thread 2thread 3
  • Seeking medical oversight before starting was something several users reflected on retrospectively3×thread 1thread 2thread 3

Based on 51 community reports · Updated

Frequently Asked Questions — TB-500

TB-500 is a synthetic peptide corresponding to residues 17–23 of thymosin beta-4 (Tb4), a 43-amino-acid protein with established roles in actin cytoskeleton regulation, wound healing, and tissue repair; no published studies have directly examined TB-500 as a compound in its own right. The Tb4 parent protein promotes actin sequestration and cell migration through beta-thymosin repeat interactions, and generates the anti-fibrotic tetrapeptide Ac-SDKP via enzymatic cleavage; TB-500 is hypothesized to retain a subset of these activities in a shorter, potentially more bioavailable fragment form.

actin binding and cellular migration facilitation — core mechanism driving tissue repair, wound healing and anti-inflammatory effects across muscle, tendon, and cardiac tissue, thymosin beta-4 C-terminal fragment — angiogenesis and systemic distribution, subcutaneous injection — frequently combined with BPC-157 in recovery research stacks.

Research on TB-500 primarily documents effects related to actin binding and cellular migration facilitation — core mechanism driving tissue repair and wound healing and anti-inflammatory effects across muscle, tendon, and cardiac tissue and thymosin beta-4 C-terminal fragment — angiogenesis and systemic distribution and subcutaneous injection — frequently combined with BPC-157 in recovery research stacks. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

For TB-500, its FDA status is Advisory Committee Recommended, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

330 providers in the directory currently offer TB-500.

Across 45 research vendors tracked on PeptideBase, TB-500 has a median price of about $7.20 per mg, typically ranging $5.63–$10.84 per mg. This reflects research-use vendor pricing, not clinical or prescription costs.

TB-500 is featured in the following research stacks on PeptideBase: BPC-157 + TB-500: Tissue Repair & Recovery, TB-500 + PEG-MGF: Muscle Repair & Regeneration.

Access

How to get TB-500

Market Pricing

45 vendors
$5.63/mgBudget
$7.20/mgMedian
$10.84/mgPremium
$5.63
$7.20
$10.84

Price per mg varies by quantity, vendor type, and formulation. Research use only.

Data verified August 2026 · TB-500 price intelligence

Compare 45 vendors →
Compare all 45 vendors →

Where to buy TB-500

330 providers
●231 Clinics●14 Telehealth●5 Pharmacies●78 Online Vendors●1 Physician●1 Global Supplier402 in stock4 on request
View all 330 providers →

Research stacks

Browse all →

Commonly stacked with

BPC-157PEG-MGF

Questions to ask your provider

Stay updated on TB-500 providers

New providers added weekly — delivered to your inbox.

Weekly research digest. No spam. Unsubscribe anytime.

Last updated

Keep exploring

Tools & Guides

TB-500 Dose Calculator

Calculate exact draw volume and doses per vial for TB-500.

How to Reconstitute Peptides

Step-by-step guide: BAC water, vial prep, and storage after mixing.

Peptide Dosage Guide

Key factors that determine dosing in clinical practice.

Peptide Storage Guide

How to store lyophilized and reconstituted peptides.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). TB-500 — Per-mg Price Benchmark. Retrieved September 11, 2026, from https://peptidebase.io/peptides/tb-500
https://peptidebase.io/peptides/tb-500MethodologyLicenseDownload JSONDownload CSV

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.